An Antibiotic Protocol Guided by a Multimodal Approach in AECOPD With Pneumonia in Intensive Care

Launched by UNIVERSITY HOSPITAL, CAEN · Mar 4, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to manage antibiotics for patients with chronic obstructive pulmonary disease (COPD) who are hospitalized in the intensive care unit (ICU) due to pneumonia. The goal is to see if a special approach using blood tests and advanced testing for germs can help reduce the number of days patients need to take antibiotics, which can have unwanted side effects. By carefully monitoring patients, the researchers hope to find a balance that treats pneumonia effectively while limiting antibiotic use.

To be eligible for this study, participants must be over 18 years old and have COPD, along with signs of pneumonia confirmed by a chest X-ray or CT scan. They should also be admitted to the hospital for less than 48 hours before entering the ICU. Patients with weakened immune systems, those who are pregnant, or those who refuse to participate will not be included. If you join the study, you can expect to follow a specific antibiotic plan while your health is closely monitored, and you will need to provide consent, either yourself or through a representative. This research aims to improve care for patients like you while being mindful of antibiotic use.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients over 18 years
• • Documented or suspected clinically COPD according to the criteria of GOLD
• • Community-acquired pneumonia defined as the presence of a radiological (i.e., chest X-ray or CTscan) infiltrates consistent with an infectious site and associated with one or more of the following items: dyspnea, cough, sputum, fever above 38 ° C, chest pain, localized crackles with or without signs of pleural effusion, higher leukocytosis at 10,000 / mm³ or leukopenia below 4000 / mm³
• • Admitted to the hospital for less than 48 hours
• • ICU Admission
• • Informed Consent signed by the patient or his representative
• Exclusion Criteria:
• • Patient immunocompromised including congenital immunodeficiency, haematologic malignancy, immunosuppressive drugs (including anticancer chemotherapy and post-transplantation therapies), neutropenia neutrophil count below 500 / mm³ secondary to chemotherapy, corticosteroids greater than 0.5 mg / kg / day for more than 10 days, HIV infection
• • Therapeutic limitation Existence
• • Minor patient or under guardianship or custody
• • Pregnant woman
• • Refusal to participate in the study
• • The inclusion of the subject in another biomedical research protocol in progress or for less than 30 day
• • Patients treated with antibiotics before ICU referral are no excluded.